Contact: l.j.jones@qmul.ac.uk

Professional interests

Louise Jones joined the Institute of Cancer in April 2004. She trained in Medicine at Leicester University and specialised in Breast Pathology undertaking a PhD at the Breast Cancer Research Unit in Leicester. The focus of her research is breast cancer and in particular the factors involved in the progression of in-situ to invasive disease with the aims of identifying 1) markers which can predict behaviour, and 2) novel therapeutic targets. Current research involves development of in-vitro models of DCIS and their use to investigate the influence of the microenvironment on tumour cell behaviour, focusing on the suppressor role of myoepithelial cells and the and the functional significance of altered myoepithelial and fibroblast phenotype in DCIS. They are also investigating the molecular classification of DCIS and its prognostic significance.

Research Team:

Funding:

Cancer Research UK, Clinical Fellowship 2007-2009 £173,000 "Molecular variations in breast cancer between women of different ethnicity"

Breast Cancer Campaign 2005-2008 £135,000 "Analysis of avb6 integrin in DCIS-associated myoepithelial cells"

Breast Cancer Campaign 2006-2008 £151,526 "Can a combination of tumour phenotyping and genotyping identify hereditary breast cancer predisposition (POSH study)?"
(held jointly with Prof. D. Eccles and Prof. A Ashworth)

The Dr. Hadwen Trust for Humane Research 2004-2007 £105,000 " Development of Multicellular 3-Dimensional Models of Normal and Pre-invasive Breast"

Breast Cancer Campaign 2005-2008 £136,00 "The Role of de novo αvβ6 Integrin Expression on Myoepithelial Cells in DCIS"

MRC 2005-2008 £170,000 "Regulation of tumourigenic capacity of breast cancer cells through epithelial-stromal interactions"

Barts and The London Charitable Trusts Foundation 2004-2007 £65,000 "The functional significance of altered Tenascin isoform expression by DCIS-associated myoepithelial cells"

Barts and The London Charitable Trusts Foundation 2006-2008 £90,000 "Molecular analysis of breast cancer in different ethnic groups"

Cancer Research Fund 2006 £6,500 "Intrinsic and acquired genetic alterations in breast cancer associated fibroblasts"

External Activities:

• Deputy Chair Scientific Advisory Board of the Breast Cancer Campaign (2006-)
• Associate Editor for Journal of Pathology (2007-)
• Member of the European Strategy for the Integration of Research on Breast Cancer (EUSTIR):
• Lead Pathologist on POSH (Predicting Outcomes in Sporadic versus Hereditary breast cancer) study: a national study of 3000 women with breast cancer <45yrs.
• Lead of translational study for IBIS 1
• Lead pathologist for FH01 breast screening study

Recent Publications:

• Bowen RL, Duffy SW, Ryan DA, Hart IR, Jones JL. Early onset of breast cancer in a group of British black women. Br J Cancer 2008;98:277-81.
• Gutierrez-Fernandez A, Fueyo A, Folgureras AR, Garabaya C, Pennington CJ, Edwards DR, Holliday DL, Jones JL, Span PN, Sweep FCGJ, Puente XS, Lopez-Otin C. MMP-8 functions as a metastasis suppressot through modulation of tumour cell adhesion and invasion. Cancer Res 2008;68(8):2755-63.
• Payne SJ, Bowen RL, Jones JL, Wells CA Predictive markers in breast cancer - the present. Histopathology 2008;52(1):82-90.
• Salama I, Malone PS, Mihaimeed F, Jones JL A review of the S100 proteins in cancer Eur J Surg Oncol 2008;34(4):357-64.
• Hughes S, Agbaje O, Bowen RL, Holliday DL, Shaw JA, Duffy S, Jones JL. Matrix Metalloproteinase single nucleotide polymorphisms and haplotypes predict breast cancer progression. Clinical Cancer Research 2007;13:6673-80.
• Holliday DL, Hughes S, Alcock RA, Shaw JA, Jones JL. Intrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: MMP-3 5A/5A genotype enhances breast cancer cell invasion. Breast Cancer Research 2007;9:R67
• Hughes S, Jones JL The use of whole genome amplified DNA as a control for methylation specific PCR, pyrosequencing, bisulfite sequencing and methylation-sensitive restriction enzyme PCR. BMC Mol Biol 2007;8(1):91
• Varghese P, Gattuso JM, Mostafa AI, Abdel-Rahman AT, Shenton KC, Ryan DA, Jones JL, Wells CA, Mair G, Kakkar AK, Carpenter R. The role of radiotherapy in treating small early invasive breast cancer. Eur J Surg Oncol 2007;34(4):369-76.
• Bowen RL, Stebbing J, Jones JL A review of the ethnic differences in breast cancer Pharmacogenomics 2006;7:935-42.
• Jones JL. Overdiagnosis and overtreatment in breast cancer: Progression of DCIS - the pathological perspective. Breast Cancer Res 2006: 8: 204.
• Shah A, Swain WA, Richardson D, Edwards J, Stewart DJ, Richardson CM, Swinson DE, Patel D, Jones JL, O'Byrne KJ. Phospho-akt expression is associated with favourable outcome in non-small cell lung cancer. Clin Cancer Res 2005;11:2930-6.
• Porter S, Scott SD, Sasoon EM, Williams MR, Jones JL, Girling AC, Ball RY, Edwards DR. Dysregulation of Adamalysin-Thrombospondin genes in human breast carcinoma. Clin Cancer Res 2004;10:2429-40.
• Swinson DE, Jones JL, Cox G, Richardson D, Harris AL, O'Byrne KJ. HIF1α in non-small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer 2004;111:43-50.
• Jones JL, Shaw JA, Pringle JH, Walker RA. Myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine down-regulation of MMP expression in fibroblasts and tumour cells. J Pathology 2003;201:562-72.
• Tai S-K, Tan OJ-K, Chow VT-K, Jin R, Jones JL,Tan P-H, Jayasurya A, Bay B-H. Metallothionein 1 and 2 isoforms in breast cancer cells: differential expression with invasive phenotype and identification of variants. Am J Pathology 2003;163:2009-19.
• Gordon LA, Mulligan KT, Maxwell-Jones H, Adams M, Walker RA, Jones JL. Breast cell invasive potential relates to the myoepithelial phenotype. Int J Cancer 2003;106:8-16.
• Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Taub N, Harris AL, O'Byrne KJ. Carbonic Anhydrase IX expression, a novel surrogate marker of tumour hypoxia, is associated with a poor prognosis in non-small cell lung cancer. J Clinical Oncology 2003;21:473-82.
• Chauhan H, Abraham A, Phillips JR, Walker RA, Pringle JH, Jones JL. There is more than one kind of myofibroblast: expression of CD34 and its relationship to αSMA and invasive potential in the breast. J Clin Pathology 2003;56:271-6.
• Squires MS, Hudson EA, Howells L, Sale S, Jones JL, Dickens M, Prigent SA, Manson MM. Influence of Curcumin on the growth and invasiveness of oestrogen-receptor-negative breast cell lines. Biochem Pharmocol 2003;65:361-76.
• Shaw JA, Udokang K, Mosquera J-M, Chauhan H, Jones JL, Walker RA. Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas. J Pathology 2002;198:450-7.
• Swinson DE, Jones JL, Richardson D, Cox G, Edwards JG, O'Byrne KJ. Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. Lung Cancer 2002;37:235-40.
• Adams M, Jones JL, Walker RA, Pringle JH, Bell SC. Altered Tenascin-C isoform expression in invasive and pre-invasive breast cancer. Cancer Research 2002;62:3289-97.
• Goddard JC, Sutton CD, Jones JL, O'Byrne KJ, Kockelbergh RC. Reduced Thrombospondin at presentation predicts disease progression in superficial bladder cancer. Eur Urology 2002;189:1-5.
• O'Byrne KJ, Cox G, Swinson D, Richardson D, Edwards JG, Lolljee J, Andi A, Koukourakis MI, Giatromanolaki A, Gatter K, Harris AL, Waller D, Jones JL. Towards a biological staging model for operable non-small cell lung cancer' Lung Cancer 2001;34:s83-9.
• Edwards JG, Cox G, Andi A, Jones JL, Walker RA, Waller DA, O'Byrne KJ. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 2001;85:863-8.
• Runswick SK, O'Hare MJ, Jones JL, Streuli CH, Garrod DR. Desmosomal adhesion regulates epithelial morphogenesis and cell positioning. Nature Cell Biology 2001;3:823-30.

<< Return to staff list